Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Sci. Signal., 4 March 2008 MEETING REPORTSMeeting Report: cGMP MattersBarbara Kemp-Harper1* and Robert Feil2
1Department of Pharmacology and Centre for Vascular Health, Monash University, Clayton, Victoria, Australia. Abstract: The second messenger cyclic guanosine 3',5'-monophosphate (cGMP) controls many cellular functions ranging from growth to contractility. Generated from guanylyl cyclases in response to natriuretic peptides or nitric oxide, cGMP transduces its effects through a number of cGMP effectors, including cGMP-regulated phosphodiesterases and protein kinases. Drugs that modulate cGMP levels are emerging as promising therapies, particularly for cardiovascular disorders. This report summarizes new data on the molecular mechanisms, (patho)physiological relevance, and therapeutic potential of the cGMP signaling system that were presented at the 3rd cGMP meeting held in June 2007 in Dresden, Germany. *Corresponding author. E-mail: Barbara.Kemp{at}med.monash.edu.au
Citation: B. Kemp-Harper, R. Feil, Meeting Report: cGMP Matters. Sci. Signal. 1, pe12 (2008). The editors suggest the following Related Resources on Science sites:In Science Signaling
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882